Compare Gilead Sciences, Inc. (GILD) vs Johnson Controls International PLC (JCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Johnson Controls International PLC — how do they compare? Gilead Sciences, Inc. trades at $136.45 (market cap $163.51B), while Johnson Controls International PLC trades at $143 (market cap $87.10B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | JCI | |
|---|---|---|
Market Cap | $163.51B | $87.10B |
Sector | Health | Industrials |
52-Week High | $155.80 | $148.21 |
52-Week Low | $108.22 | $103.24 |
Enterprise Value | $178.05B | $95.93B |
Dividend Yield | 2.49% | 1.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
JCI trades at $139.67, down 3.84% on the day, with a bullish technical signal from moving averages and support at $140. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $1.32. Revenue for 2025 was $23.60B, net income $3.29B, and profit margin expanded to 13.94%. Analyst consensus is strongly bullish with a $158.29 price target and no sell ratings among 45 analysts. Recent news highlights innovation awards and dividend declarations.
JCI presents a favorable outlook with consistent earnings beats, strong analyst support, and exposure to growth areas like energy efficiency. Risks include high valuation multiples (P/E 43.66) and increasing debt-to-asset ratio (26.06% in 2025). The stock's proximity to the $140 support level offers a potential entry point, but macroeconomic headwinds and execution risks in competitive markets warrant caution for investors seeking stable returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →
